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Abstract 
The management of pain and inflammation in haemophilic arthropathy is challenging due to 
the lack of anti-inflammatory analgesic agents perfectly suitable for this population.  Non-
steroidal anti-inflammatory drugs (NSAIDs) are widely used in the management of arthritis 
due to their analgesic and anti-inflammatory effects.  Their use in persons with haemophilia 
(PWH), however, is limited due to increased risk of bleeding mainly from the upper 
gastrointestinal (UGI) tract. Cyclooxygenase-2 (COX-2) selective NSAIDs which have 
comparable analgesic effect to traditional NSAIDs (tNSAIDs) but with less UGI bleeding have 
been considered to be a suitable option for treatment of haemophilic arthropathy. COX-2 
inhibitors, however, have an increased in the risk of cardiovascular (CV) disease. Although 
the atherosclerotic burden in PWH is similar to that in the general population, the risk of CV 
related deaths is lower. PWH have a higher risk of GI bleeding and lower risk of thrombotic 
disease compared to general population. Therefore, when PWH require anti-
inflammatory/analgesic agents, it seems reasonable to use lowest possible dose of COX-2 
inhibitors for the shortest period  with a proton pump inhibitor cover (provided they do not 
have renal impairment or additional risk factors for CV disease) prior to starting COX-2 
inhibitors. H.pylori infection should be tested for and eradicated prior to starting NSAID 
treatment in PWH. Furthermore, regular blood pressure and renal function test monitoring 
is required during COX-2 inhibitor treatment. 
 
 
 
  
3 
 
 Introduction 
Haemophilia A and B are characterised by bleeding, primarily into joints and muscles. Joint 
bleeding accounts for >90% of all serious bleeding episodes in person with haemophilia 
(PWH)[1]. Primary prophylaxis with factor concentrate has been shown to reduce the risk of 
haemophilic arthropathy [2]. However, despite regular prophylaxis, some PWH still develop 
arthropathy as do older patients who did not have primary prophylaxis. Haemophilic 
arthropathy is a chronic inflammatory and degenerative arthritic process that directly 
affects quality of life of the majority of adults with severe haemophilia [3]. Intra-articular 
haemorrhage causes synovial inflammation with hypertrophy and growth of friable new 
blood vessels that are vulnerable to further bleeding. Chronic synovitis predisposes the joint 
to recurrent bleeding and inflammation; within the joint, release of proteolytic enzymes 
activate osteoclasts and lead to destruction of cartilage matrix. Chronic inflammation causes 
fibrosis, cartilage degeneration and joint damage similar to osteoarthritis, with pain and 
reduced mobility. Chronic arthropathy is the main co-morbidity in the ageing  PWH and joint 
damage increases with age in an almost linear fashion in both severe and moderate 
haemophilia [4]. Age-related osteoarthritic changes include degenerative joint changes, 
osteoporosis, muscle atrophy or sarcopenia and muscle weakness. Disturbance of gait and 
balance also contribute to the increasing pain and advanced haemophilic arthropathy in 
PWH [5]. Thus reducing pain and chronic inflammation are major components of 
haemophilic arthropathy management in addition to coagulation factor replacement for 
acute bleeding and prophylaxis. 
Management of pain and inflammation in haemophilic arthropathy is challenging due to 
lack of anti-inflammatory analgesic agents perfectly suitable for this population[6].  Non-
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steroidal anti-inflammatory drugs (NSAIDs) have been widely used in the management of 
arthritis due to their analgesic and anti-inflammatory effects. However, their use in PWH is 
limited due to increased risk of bleeding mainly from the upper gastrointestinal (UGI) tract 
[6] as a result of non-selective inhibition of cyclooxygenase (COX) 1 and 2,  decrease platelet 
aggregation via suppression of  COX-1 dependent thromboxane A2 and also inhibition of the 
production of gastroprotective prostaglandins primarily formed by COX-1 (Figure 1). The 
discovery of COX-2 selective NSAIDs which have comparable analgesic effect to tNSAIDs 
with no inhibition of the gastroprotective prostaglandins are alternatives for the treatment 
of haemophilic arthropathy [7]. 
 Although, the World federation of haemophilia (WFH) guidelines for the management of 
haemophilia suggest the use of selective COX- 2 inhibitors in the management of 
haemophilic arthropathy [8], there are no evidence based guidelines in pain management in 
PWH [9;10].  Compared to tNSAIDs, COX-2 inhibitors (coxibs) have significantly lower 
incidence of gastroduodenal ulcer complications and UGI bleeding [6;11;12]. Current 
evidence suggests that tNSAIDs and selective COX-2 inhibitors have a similar incidence of 
cardiovascular (CV) and renovacular adverse events [13;14]. In addition, there is emerging 
evidence that NSIADs are associated increase of stroke [15]. 
 The epitome of age-related morbidity, CV disease, is a leading cause of mortality in elderly 
individuals, and presents a particular challenge when it occurs in PWH. Whilst the exact 
incidence of CV disease in haemophilia is unknown, incidence rates of conditions such as 
ischaemic heart disease (IHD) have steadily risen over the last 20-30 years, suggesting that 
cardiac problems are increasingly relevant in these individuals [6]. In addition, chronic renal  
disease can occur with increasing frequency in PWH in addition to the usual risk factors 
related to general population, because of haematuria, structural renal damage and frequent 
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use of  antifibrinolytic drugs [16].  The aim of this review is to examine the available 
evidence on use of NSAIDs patients with haemophilia, risk of GI bleeding, CV risk and other 
risks associated with these drugs and to address the question of whether there are any 
NSAIDs that are more suitable for use in PWH. To achieve this a literature search was carried 
out on PubMed for publications in the last 30 years using the following words or phrases: 
h(a)emophilia, arthropathy, pain management of haemophilia, NSAIDs, COX-2 inhibitors, 
gastrointestinal bleeding, cardiovascular risk, stroke, renal disease, management of 
haemophilic arthropathy, Histamine receptor2 blockers, proton pump inhibitors, 
misoprostol in preventing NSAID related bleeding and risk of thrombosis in haemophilia. 
 
What is the risk of GI bleeding in the general population and by how much is this increased 
when using NSAIDs? 
UGI bleeding is defined as bleeding from a gastrointestinal source proximal to the ligament 
of Treitz [17].  Bleeding from UGI is four times commoner than bleeding from lower GI tract 
[11;17]. Peptic ulcer disease remains the most common cause of UGI bleeding accounting 
for 21% to 40% of all bleeding episodes. The incidence of acute UGI bleeding in the UK 
ranges between 84-172 per 100,000 per year causing 50-70,000 hospital admissions per 
year [18]. Helicobacter pylori (H. pylori) infection and NSAID use are the most common 
causes of peptic ulcer disease [19;20]. The risks of GI and CV adverse effects are through to 
be due to the same mechanisms that NSAIDs exert their beneficial effects as anti-
inflammatory and analgesic agents ie:  by inhibition of COX-dependent prostaglandin 
synthesis [21]. COX-1 inhibition is associated with decreased platelet aggregation and GI 
toxicity increasing UGI bleeding [22;23]. Prostaglandin I2 (PG I2), has cardioprotective 
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properties, synthesised by COX-2 and promotes vasodilation and inhibition of platelet 
aggregation [22].  
A meta-analysis of 16 randomised controlled trials (RCTs) involving almost 800,000 patients 
taking NSAIDs for at least 4 days, reported an odds ratio (OR) of 5.36(95% CI, 1.79-16.1) vs 
placebo for severe UGI complications, including perforations, clinically relevant ulcers and 
bleeding [24]. The risk of GI complications with tNSAIDs is present from the first dose (with 
both short-term and long-term use), and strategies to prevent GI complications should be 
considered regardless of the duration of therapy [14]. Substitution of a coxib for a tNSAID 
has been shown to decrease the risk of GI toxicity including small but significant reduction 
of dyspepsia [25].  A Cochrane meta-analysis that compared the GI safety of coxibs with 
tNSAIDs concluded that coxibs were associated with significantly fewer gastroduodenal 
ulcers and fewer ulcer complications (including perforation, obstruction and bleeding), as 
well as fewer treatment withdrawals caused by GI symptoms when compared with tNSAIDs 
[26]. While protecting the stomach, proton pump inhibitors (PPI) do not prevent NSAID-
induced damage in the rest of the gastrointestinal tract. A substantial number of patients 
who need NSAIDs are also taking low-dose aspirin for cardiovascular prophylaxis. From a GI 
perspective, the combination of aspirin plus a coxib provides a preferred option compared 
to aspirin plus a t-NSAID, for patients at high GI risk [14].  
Pharmacokinetic characteristics of NSAIDs influence their safety and tolerability.  NSAIDs 
with longer half-life and sustained-release forms such as diclofenac are associated with 
increased gastro-erosive effects as well as higher risk of bleeding and perforation [27;28]. A 
systematic review of observational studies on NSAIDs and upper GI bleeding/perforation 
published between 2000 and 2008 estimated the relative risk (RR) of upper GI 
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bleeding/perforation was 4.50 (95% confidence interval [95% CI] 3.82-5.31) for tNSAIDs and 
1.88 (95% CI 0.96-3.71) for coxibs [28]. There is strong evidence to suggest that the GI and 
CV side effects and renal damage of NSAIDs are related to total daily dose [29-32]. Daily use 
of diclofenac sodium >75mg/day was associated with a 2-3-fold increase in GI complications 
compared with low or medium doses [29;32]. 
In addition to H. pylori infection which almost doubles the risk of GI bleeding [33], other risk 
factors that contribute to NSAIDs induced GI bleeding include,  increasing age, co-existing 
medical illnesses such as ischaemic heart disease, congestive heart failure, renal  failure, 
hepatic failure, thrombocytopenia or other haemostatic defects such as underlying bleeding 
disorders [34].  Patients who develop gastric or duodenal ulcers with or without bleeding 
should be tested for H. pylori infection and eradication therapy should be given [35]. A 
meta-analysis of randomized trials showed that H. pylori eradication therapy for prevention 
of recurrent ulcer bleeding is significantly more effective than short-term anti-secretory 
therapy alone (rebleeding 4.5 vs. 23.7%; odds ratio [OR] 0.18, 0.10–0.35) [36].  In those 
individuals who are at significant risk of developing UGI bleeding with NSAIDs, it is 
recommended that testing for H. pylori infection prior to commencing NSAIDs is performed. 
If positive, the infection should be eradicated prior to staring NSAIDs and a COX-2 inhibitor 
plus a PPI should be used [34;35]. 
In patients who develop NSAID induced UGI bleeding, NSAIDs should be stopped and a PPI 
should be commenced [35]. Those who require continued NSAIDs, COX-2 inhibitors with a 
PPI is recommended to reduce further risk of GI bleeding [34;35]. Combination of a COX-2 
inhibitor and a PPI is associated with lower GI complications compared to a COX-2 inhibitor 
alone or combination of tNSAIDs plus a PPI [34]. PPIs do not offer protection beyond the 
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UGI and this has been shown in a large prospective RCT that found that clinically significant 
bleeding events occurring throughout the GI track were significantly greater in patients 
taking tNSAIDs in combination with omeprazole than in patients taking celecoxib [37;38]. 
The recommended strategies to decrease GI toxicity in NSAID users include co-therapy with 
misoprostol, histamine type-2 receptor antagonists (H2RAs) or PPIs and/or the use of COX-2 
inhibitors [39;40]. The American College of Gastroenterology recommends that patients 
requiring NSAID therapy who are at high risk of bleeding should receive alternative therapy 
or, if anti-inflammatory treatment is absolutely necessary, a selective coxibs and/or co-
therapy with misoprostol or high-dose PPI should be used [40].  Table 1 shows the tNSAIDs, 
COX-2 inhibitors, H2-receptors blockers and proton pump inhibitors available in UK.  
 
What is the baseline risk of GI bleeding in haemophilia without NSAIDs?  
UGI haemorrhage can occur in up to 25% of PWH and recurrent bleeding is common with a 
high mortality rate [41]. The absolute risk for developing UGI bleeding in a PWH is unknown. 
However, in a multicentre study with 2285 patients with haemophilia, there was a 1.3% 
annual incidence of clinically important UGI bleeding events [6]. This incidence is nearly 10 
times greater than the 0.1% UGI bleeding rate reported in those without haemophilia 
(general population) [42]. The frequency and severity of bleeding may vary depending on 
the severity of haemophilia but there are no large studies exploring this issue. Mittal et al, in 
early 1980s, studied 243 PWH and reported  that the type of haemophilia (A or B) and the 
presence or absence of an inhibitor or blood group had no relationship to the risk of GI 
bleeding [43].  However,  this study reported  that patients with severe haemophilia were at 
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higher risk  of developing GI bleeding than mild haemophilia [43]. The possible explanations 
for this increased risk in severe haemophilia were lower threshold for bleeding in severe 
haemophilia with any underlying gastrointestinal pathology such as peptic ulcer disease, use 
of frequent analgesia such as NSAIDs for severe chronic arthropathy and development of 
chronic liver disease due to hepatitis transmitted by plasma or concentrates. Spontaneous 
haemorrhage in the bowel wall in severe haemophilia has been reported to occur in  4.85% 
of patients [43]. PWH continue to have arthropathic pain, especially those who have not had 
the benefits of primary prophylaxis. Despite the high prevalence of pain with significant 
impact on the quality of life of PWH, no high level evidence based guidelines on pain 
management of these patients are available.  Use of NSAIDs, the standard analgesic and 
anti-inflammatory agents that are used in patients with arthritis without haemophilia, carry 
the additional risk of bleeding in PWH in addition to NSAIDs associated increased risk of 
cardiovascular, renal and other complications present also in the general population. 
   
What is the risk of NSAID related bleeding in Haemophilia?  
GI bleeding is often linked to the use of tNSAIDs such as ibuprofen, diclofenac sodium used 
to relieve pain associated with haemophilic arthropathy [6]. As well as UGI bleeding they 
may increase the risk of bleeding into haemophilic joints [44].  Studies assessing the safety 
and efficacy of NSAIDs in PWH are limited by small number of patients. A randomised, 
placebo controlled crossover study of 20 patients (age 17-40 years) with severe or moderate 
haemophilia A or B  assessing the safety and efficacy of 1600mg ibuprofen daily for 16 
weeks found no increase in the frequency of bleeding. Nobody had GI bleeding but one 
patient had dyspepsia and withdrew from the study. Due to the small number in this study, 
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it is difficult to draw a valid conclusion on safety of ibuprofen in PWH [45].  In a double blind 
controlled clinical trial using ibuprofen and placebo, pain was markedly reduced as assessed 
by pain score in eight out of nine patients using ibuprofen without significant bleeding or 
change in the use of factor concentrate [46]. Case reports of excessive  bruising in one 
patient using ibuprofen [47] and three cases of GI bleeding after the use of over the counter 
NSAIDs have been published [48]. A multicentre, prospective, observational study of 2285 
patients with haemophilia  found that the risk of UGI bleeding was significantly increased 
after less than one month use of  tNSAID (OR: 3.66; 95% confidence interval [CI]:1.1-11.9) 
but not with COX-2 inhibitors [6]. Furthermore it was reported that the relative risk of GI 
bleeding was significantly and independently increased with age >46years (3.5; 95% CI: 1.1-
10.6) and hepatic decompensation (4.4; 95% CI: 1.7-11.6). Presence of H. pylori positivity 
increased the likelihood of UGI bleeding but this did not reach statistical significance (odds 
ratio: 4.6; 95% CI: 0.3-83.9) [6]. Based on these finding the authors concluded that COX-2 
inhibitors are safer alternative analgesic and anti-inflammatory agents for PWH with 
arthropathy [6]. Another small study of 12 patients using retrospective chart review found 
that celecoxib (COX-2 inhibitor) was safe and effective in treating chronic synovitis and joint 
pain in adults and children with haemophilia [49]. 
The first line of analgesia in PWH is often paracetamol/acetaminophen and this is also 
recommended by the latest WFH guidelines [8].  In addition to being a less effective 
analgesic agent, paracetamol may not be as safe in terms of gastrointestinal and 
cardiovascular aspects alongside its well-known hepatotoxicity [34].  A nested case control 
study found that paracetamol in any dose is associated with small but significantly increased 
risk of UGI complications (RR, 1.3; 95% CI 1.1-1.5). The RR was 3.6 (95% CI 2.6-5.1), if the 
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dose of paracetamol  dose was more than 2g a day [50]. Regular use of paracetamol is 
associated with an increased risk of hypertension in both males [51] and females [52]. These 
side effects could be  explained by the finding that paracetamol is a selective 
cyclooxygenase (COX)-2 inhibitor in humans [53]. This information suggests that 
paracetamol in PWH should be used with caution and risks and benefits of individual 
patients should be assessed at least when they are requiring frequent/high doses of 
paracetamol. The WFH 2012 guidelines on general care and management of haemophilia 
recommend COX-2 inhibitors pain due to chronic haemophilic arthropathy and advise 
avoiding other NSAIDs. Several expert reviews on management of haemophilic arthropathy 
also support the use of COX-2 inhibitors to relive the pain in PWH [4;9;10;54;55].  However, 
due to the CV and renal risk of COX-2 inhibitors caution should be used in patients with 
hypertension and renal impairment.  Due to the risk of GI bleeding PWH should receive 
COX-2 inhibitor and/or co-therapy with misoprostol or high-dose PPI [40]. Although, the 
prevalence of H.pylori infection is similar in PWH to patients without haemophilia [56], PWH 
are at higher risk of bleeding due to due to underlying coagulopathy [57]. Screening for and 
eradication of H.pylori prior to starting COX-2 inhibitors is  recommended [40].   
 
Cardiovascular, stroke and renal risks associated with NSAIDs in general population 
In 2005, the European Committee for Medicinal Products for Human Use (CHMP) recognised 
an increased risk of thrombotic events, such as myocardial infarction and stroke with COX-2 
inhibitors [58].  As a result, CHMP stated that COX-2 inhibitors must not be used in patients 
with established ischaemic heart disease and/or cerebrovascular disease [58]. The following 
year, they concluded that tNSAIDs also carry an increased risk of thrombosis, especially   
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when these drugs are used at high doses for a long period [59]. A large meta-analysis of 
cohort and nested case control studies found an increased risk of CV events for all tNSAIDs 
and COX-2 inhibitors [60]. Several other meta-analyses also found that tNSAIDs and COX-2 
inhibitors have similar CV risk [61-63]. Naproxen appeared to be the least harmful in relation 
to CV risk, but this advantage has to be weighed against higher GI toxicity compared to COX-
2 inhibitors [64].  There are no published randomised control trials specifically designed to 
compare CV, GI and renal safety of tNSAIDs and COX-2 inhibitors. The Prospective 
Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen 
(PRECISION) [https://clinicaltrials.gov/NCT00346216] study is currently running and is 
deigned to answer the question of overall benefit to risk balance of celecoxib when 
compared to two of the most commonly prescribed tNSAIDs in the treatment of arthritis 
pain. The thrombotic and renal risk of both tNSAIDs and COX-2 inhibitors are related to dose 
and duration of treatment. A pooled analysis of data from 7950 patients in 6 placebo 
controlled trials comparing celecoxib with placebo in conditions other than arthritis with a 
follow-up up to at least 3 years, found that  the CV risk (primary end points  combination of 
CV death, myocardial infarction, stroke, heart failure or thromboembolic events) increased 
with dose regimen (p=0.0005). Risk was lowest for celecoxib 400mg once daily dose (hazard 
ratio, 1.1; 95% CI, 0.6 to 2.0) and highest for 400mg twice daily dose (hazard ratio, 3.1; 95% 
CI, 1.5 to 6.1). The risk was further increased in those patients who had higher baseline risk 
of CV disease [65]. 
The benefits of low dose aspirin in secondary prevention of CV disease clearly outweigh the 
risk [66] and COX-2 inhibitors do not interfere with the anti-platelet effect of low dose 
aspirin [34].  However, tNSAIDs being COX-1 inhibitors impair thromboxane A2 synthesis 
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hence platelet aggregation.  It has been shown that with the exception of diclofenac and 
meloxicam, almost all other tNSAIDs can interfere with the anti-platelet effect of aspirin. 
COX-2 inhibitors are a better anti-inflammatory and analgesic option if anti-inflammatory 
drugs are essential for patients taking aspirin for CV protection [34]. It should be noted, 
however, that in 2005 the CHMP advice stated that ‘’COX-2 inhibitors must not be used in 
patients with established ischaemic heart disease and/or cerebrovascular disease’’ [58]. 
Due to their increased cardiovascular risk, which is dependent on the dose, duration of 
therapy, and base-line cardiovascular risk, both t-NSAIDs and coxibs should be used with 
caution in patients with underlying prothrombotic states and/or concomitant cardiovascular 
risk factors. [34].  
The nephrotoxicity of NSAIDs is well recognised. A case control study using data from a 
general practitioners database found that patients on NSAIDs had a 3-fold increased risk of 
developing acute renal failure compared to non-users. Patients on higher doses of NSAIDs 
had slightly higher risk (RR, 3.4; 95% CI, and 1.6-7.0) compared to low and medium doses 
(RR, 2.5; 95% CI, and 1.2-5.4) [67]. The nephrotoxicity of NSAIDs is mediated via nonspecific 
blocking of cyclooxygenase, subsequent inhibition of prostaglandin synthesis leading to 
vasoconstriction, and reversible renal impairment in volume-contracted states [68;69]. This 
may lead to acute tubular necrosis and acute renal failure. NSAIDs also produce interstitial 
nephritis and papillary necrosis, resulting in chronic renal failure [70].  Renal toxicity is not 
limited to tNSAIDs and clinical trials with celecoxib have shown renal effects similar to those 
observed with comparator tNSAIDs [71]. Patients at greatest risk for renal toxicity are those 
with impaired renal function, heart failure, liver dysfunction, those taking diuretics, ACE-
inhibitors, angiotensin II receptor antagonists, and the elderly [71].  As the incidence of 
  
14 
 
renovascular adverse effects with t-NSAIDs and coxibs is similar, blood pressure should be 
monitored and managed appropriately in patients taking these drugs [34]. 
 
What is the risk of cardiovascular, stroke and renal disease in patients with haemophilia? 
The risk factors for myocardial infarction and stroke such as diabetes mellitus, obesity, 
hypercholesterolemia and smoking in PWH appear to be similar to those of the general 
population [72].  However, a cross-sectional study of a cohort of 701 haemophilia patients 
aged 30 years or older found that the prevalence of hypertension is higher in PWH than in 
the general population [73]. The cause of this increased prevalence is unknown. Blood 
pressure measurements should be part of standard care in haemophilic patients aged 30 
years or older. The low level of factor VIII or IX in haemophilia A and B which is associated 
with reduced thrombin generation should at least theoretically protect against a thrombotic 
risk [74].  Several surveys and cohort studies in PWH have shown that CV mortality was 
lower compared to general population [75]. Furthermore, the incidence of CV disease was 
higher in patients with mild haemophilia (3.4%) than moderate (0.7%) and severe (0.4%) 
disease (p<0.001) [76]. PWH have the same degree of atherosclerosis burden as the general 
population but there is reduced CV disease and CV morality in PWH [74]. It is postulated 
that the reduced thrombin generation in PWH may favourably affect the plaque 
phenotype/behaviour rather than plaque load.  
In a surveillance study from 1993 to 1998, it was reported that PWH had a 50 fold increased 
risk of death from renal disease compared to the general population [77]. PWH have several 
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risk factors contributing to renal damage including bleeding in the renal tract, increased 
prevalence of hypertension, NSAID use and HIV infection.  
Concluding remarks on NSAID use in Haemophilia 
tNSAIDs increase the risk of bleeding and other complications throughout the entire GI   
tract and the risk is  increased further in patients with additional comorbidities such as  
coagulopathies. Even when tNSAIDs are used with PPI, the protection against GI bleeding is 
only in the UGI tract. COX-2 inhibitors carry a lower risk of GI bleeding compared to tNSAIDs 
and if used in patients at higher risk of GI bleeding they have a better outcome. Both 
tNSAIDs and COX-2 inhibitors carry increased risks of thrombotic and renal complications.  
The increased risk is GI, CV and renal complications vary across individual agents, dose, 
duration of treatment and conditions of use. PWH have higher risk of GI bleeding and renal 
disease while having a lower risk of thrombotic disease compared to the general population. 
Therefore, if a PWH requires anti-inflammatory/analgesic agents, it seems reasonable to use 
the lowest possible dose of COX-2 inhibitor for a short period of time with PPI cover, 
provided they do not have renal failure and additional risk factors for CV disease. Table 5 
shows the estimated incidence of GI bleeding and MI or stroke in patients with haemophilia 
by NSAID type usage.  Prior to starting COX-2 inhibitors, it is recommended to screen for, 
and if positive eradicate, H. pylori infection in PWH. Furthermore, regular blood pressure 
monitoring and renal function testing are required once COX-2 inhibitors are commenced. It 
must be appreciated that there is a balance between managing pain effectively to improve 
the quality of life in PWH and minimising the risk adverse events associated with these 
drugs. 
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Figure 1. Effects on cyclooxygenase inhibition on vascular system and gastric mucosa 
tNSAIDs: traditional  non-steroidal anti-inflammatory drugs;  COX : cyclo-oxygenase  
Adapted from Park et al; Vasc Health Risk Manag. 2014 [78]. 
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Table 1. tNSAIDs, COX-2 inhibitors, H2-receptors blockers and proton pump inhibitor 
available in UK  
tNSAIDs Non-COX selective Indomethecin,Diclofenac, 
Piroxicam, Ibuprofen, 
Naproxen ,Mefenamic acid 
 
Preferential COX-1  Aspirin 
 
Preferential COX-2 Nabumetone, Meloxicam, 
Etodolac, Paracetamol 
 
Selective COX-2 inhibitors Etoricoxib, Celecoxib, Parecoxib 
 
H2-receptor blocker Cimetidine, Famotidine, Nizatidine, Ranitidine 
 
Proton Pump Inhibitors (PPI) Esomeprazole, Lansoprazole, Omeprazole, 
Pantoprazole, Rabeprazole Sodium 
tNSAIDs: traditional  non-steroidal anti-inflammatory drugs;  COX : cyclooxygenase;  
H2: Histamine2  
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Table 2. Upper gastrointestinal bleeding risk with individual NSAIDs in general population 
Name of the non-steroidal anti-
inflammatory drug 
Relative risk (95% CI) 
Celecoxib 1.0 (0.4-2.1) 
 
Diclofenac 2.6 (1.5-4.6) 
 
Ibuprofen 3.1 (2.3-4.2) 
 
Naproxen 7.3 (4.7-11.4) 
 
Ketoprofen 8.6 (2.5-29.2) 
 
Indomethecin 9.0 (3.9-20.7) 
 
Meloxicam 9.8 (4.0-23.8) 
 
Piroxicam 12.6 (7.8-20.3) 
 
Ketorolac 14.1 (5.2-39.9) 
 
Adapted from Lanas et al; Gut. 2006 [79] 
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Table 3. What is known about risks of using NSAIDs in general population and person with 
haemophilia 
a) NSAIDs increase the risk of GI bleeding and tNSAIDs carry a higher risk of 
bleeding than COX-2 inhibitors. The risk is dose and treatment duration 
dependent 
b)   Both tNSAIDs and COX-2 inhibitors have an increased risk of thrombotic and 
renal complications. These risks are dose and treatment duration dependent. 
c)  The risk of GI bleeding and renal disease are higher while CV disease and 
related deaths are lower in PWH compared to the general population 
tNSAIDs: traditional  non-steroidal anti-inflammatory drugs;  COX : cyclooxygenase;  
GI: gastrointestinal; CV: cardiovascular; PWH: person with haemophilia  
 
 
 
 
 
 
 
 
 
 
  
20 
 
Table 4. Summary of recommendations on use of NSAIDs in person with haemophilia  
a) Balancing the pain benefit versus the increase risk of adverse events, COX-2 
inhibitors at the lowest possible dose and for the minimum treatment duration are 
the most reasonable option to control arthritic pain in PWH 
b) Use of PPI in all PWH but especially severe/moderate haemophilia when using 
tNSAIDs or coxibs is recommended 
c) Screening and eradication of H.pylori infection is recommended in PWH prior to 
commencing NSAIDs 
d) Regular blood pressure and renal function test monitoring are required once COX-2 
inhibitors are commenced 
PPI: proton pump inhibitors; NSAIDs: non-steroidal anti-inflammatory drugs;  
COX : cyclooxygenase; PWH: person with haemophilia  
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Table 5. The estimated  incidence of GI bleeding and MI or stroke in patients with 
haemophilia by NSAID type usage. 
 
Group Relative risk Absolute risk – incidence per year per 1000 patients 
  Age 30 Age 50 Age 70 
 Gastrointestinal bleeding 
General population 
[80] 
 
- 0.87 1.01 2.47 
Haemophilia with 
no NSAIDs [6, 42] 
10.0 8.7 10.1 24.7 
Haemophilia plus 
diclofenac [79] 
3.1 27.0 31.3 76.6 
Haemophilia plus 
ibuprofen [79] 
4.1 35.7 41.4 101.3 
Haemophilia plus 
naproxen [79] 
7.3 63.5 73.7 180.3 
Haemophilia plus 
indomethacin [79] 
9.0 78.3 90.9 222.3 
Haemophilia plus 
celecoxib [79] 
1.0 8.7 10.1 24.7 
 Risk of MI or stroke 
General population 
(Males only)  [81] 
- 0.3 4.5 19.5 
Haemophilia with 
no NSAIDs [82] 
0.59 0.18 2.66 11.51 
Haemophilia + 
diclophenac [60] 
1.4 0.25 3.72 18.11 
Haemophilia + 
ibuprofen [60] 
1.18 0.21 3.14 13.58 
Haemophilia + 
naproxen [60] 
1.09 0.20 2.90 12.55 
Haemophilia + 
indomethacin [60] 
1.3 0.23 3.46 14.96 
Haemophilia + 
celecoxib [60] 
1.17 0.21 3.11 13.47 
. Extreme caution should be exercised in using this table due to many limitations including 
the assumption that the risks are multiplicative, are not based on absolute measure in 
patients with haemophilia, the baseline GI risk is based on a single population and where 
meta-analysis data are used not all data included was uniform in the magnitude of the risk. 
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